Pharmaceutical Co-Crystals: An Overview on Synthesis and Regulatory Aspects
Co-Crystals are crystalline materials formed by bonding between a drug and co-former. This alternative approach help to overcome many issues arise during preformulation like solubility, dissolution characteristics, compressibility, and product stability. The co-crystal engineering is done by following hydrogen bonding rules and molecular structure by using Cambridge structural database. co-crystals can be synthesized by solution mediated and solvo thermal methods. The formation of the crystals was analyzed by some analytical techniques like FTIR, DSC etc. The regulation of pharmaceutical co-crystals and their formulations shows considerable effect on development and quality control strategies and also to the value of intellectual properties.
Keywords: co-crystals, crystallization, Heterosynthons, stoichiometry
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).